View Future GrowthKBIO LABS 過去の業績過去 基準チェック /06KBIO LABSは24.5%の年平均成長率で業績を伸ばしているが、Consumer Durables業界はgrowingで3.7%毎年増加している。売上は成長しており、年平均38.2%の割合である。主要情報24.51%収益成長率46.66%EPS成長率Consumer Durables 業界の成長8.99%収益成長率38.20%株主資本利益率-2.66%ネット・マージン-2.83%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.分析記事 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...すべての更新を表示Recent updatesお知らせ • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea分析記事 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).分析記事 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.分析記事 • Apr 08Here's Why We're Not At All Concerned With KBIO's (KOSDAQ:038530) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.お知らせ • Mar 12KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea分析記事 • Jan 08Market Might Still Lack Some Conviction On KBIO COMPANY Inc. (KOSDAQ:038530) Even After 38% Share Price BoostKBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m).Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years.New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m).分析記事 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m).分析記事 • Jul 16KBIO (KOSDAQ:038530) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Mar 27We're Not Worried About KBIO's (KOSDAQ:038530) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m).New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m).Board Change • Jul 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 10Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim CorporationOn April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.Is New 90 Day High Low • Mar 03New 90-day low: ₩1,335The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period.お知らせ • Jan 23Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in fundingOn January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024.お知らせ • Jan 20Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021.Is New 90 Day High Low • Jan 11New 90-day low: ₩1,355The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period.お知らせ • Oct 13Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company.Is New 90 Day High Low • Oct 08New 90-day high: ₩1,985The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period.お知らせ • Sep 22Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdOn September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.お知らせ • Sep 09Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdGold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company.収支内訳KBIO LABS の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A038530 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2682,639-2,3409,3941,33331 Dec 2587,312-3,2009,4231,32130 Sep 2583,849-12,47510,8491,39630 Jun 2582,789-12,08810,6441,35631 Mar 2581,012-7,01110,5051,15331 Dec 2476,514-6,79110,3991,13230 Sep 2458,3181,5936,91279930 Jun 2448,288-1935,76054131 Mar 2435,821-10,7114,88426631 Dec 2327,325-11,8173,674031 Mar 2329,974-4,9882,183031 Dec 2231,129-7,0152,678030 Sep 2230,729-11,7926,399030 Jun 2223,325-17,4796,551031 Mar 2216,435-12,2626,801031 Dec 218,722-16,5856,311030 Sep 196,381-8,7886,655030 Jun 192,853-7,1995,950031 Mar 194,153-5,5925,154031 Dec 185,708-4,3805,301030 Sep 182,446-9014,275030 Jun 184,293-4193,530031 Dec 175,031-9651,762031 Dec 1518,635-10,2167,7997630 Sep 1519,097-7,5034,75717130 Jun 1520,955-9,1145,106171質の高い収益: A038530は現在利益が出ていません。利益率の向上: A038530は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A038530は利益を出していないが、過去 5 年間で年間24.5%の割合で損失を削減してきた。成長の加速: A038530の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A038530は利益が出ていないため、過去 1 年間の収益成長をConsumer Durables業界 ( -19.1% ) と比較することは困難です。株主資本利益率高いROE: A038530は現在利益が出ていないため、自己資本利益率 ( -2.66% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-durables 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 02:16終値2026/06/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KBIO LABS Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
分析記事 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...
お知らせ • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea
分析記事 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).
分析記事 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).
Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.
分析記事 • Apr 08Here's Why We're Not At All Concerned With KBIO's (KOSDAQ:038530) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea
分析記事 • Jan 08Market Might Still Lack Some Conviction On KBIO COMPANY Inc. (KOSDAQ:038530) Even After 38% Share Price BoostKBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m).
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years.
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m).
分析記事 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m).
分析記事 • Jul 16KBIO (KOSDAQ:038530) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Mar 27We're Not Worried About KBIO's (KOSDAQ:038530) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m).
New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m).
Board Change • Jul 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 10Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim CorporationOn April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.
Is New 90 Day High Low • Mar 03New 90-day low: ₩1,335The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period.
お知らせ • Jan 23Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in fundingOn January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024.
お知らせ • Jan 20Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021.
Is New 90 Day High Low • Jan 11New 90-day low: ₩1,355The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period.
お知らせ • Oct 13Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company.
Is New 90 Day High Low • Oct 08New 90-day high: ₩1,985The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period.
お知らせ • Sep 22Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdOn September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.
お知らせ • Sep 09Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdGold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company.